AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Anaplastic Lymphoma Kinase (ALK) Inhibitors: Worldwide Market Analysis & Forecast 2019-2023 with F. Hoffmann-La Roche, Novartis, Pfizer, and Takeda Pharmaceutical Co Dominating - ResearchAndMarkets.com

May 21, 2019

DUBLIN--(BUSINESS WIRE)--May 21, 2019--

The “Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023.

The high prevalence of lung cancer is one of the key factors expected to trigger market growth

The increasing need for treatments coupled with the advances in therapeutics such as targeted therapy is encouraging more and more patients to undergo treatments using ALK inhibitor therapeutics. As a result, owing to the strong incidence rates of the disease and the increasing drug approvals, global ALK inhibitors market will register considerable growth during the forecast period.

Presence of patient assistance programs

Patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of ALK inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth.

Adverse effects associated with therapeutics

Despite being highly efficacious, ALK inhibitors used for treatment NSCLC are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.

Competitive Landscape

The market appears to be concentrated. ALK inhibitors have demonstrated efficacy in the oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials.

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/qsnck0

View source version on businesswire.com:https://www.businesswire.com/news/home/20190521005807/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Enzymes,Hematology

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/21/2019 12:58 PM/DISC: 05/21/2019 12:58 PM

http://www.businesswire.com/news/home/20190521005807/en

All contents © copyright 2019 The Associated Press. All rights reserved.